This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Close Message for pharmaceutical industry jobs
Pharma-Search Ltd is dedicated to putting job seekers looking for pharmaceutical industry jobs in touch with recruiters and employers.

Similar jobs you may be interested in:

CMC Strategy Leader- Late Stage Biologics (Germany)
South East
Head of USP Manufacturing - Biopharma - Shanghai
Head of DSP Manufacturing - Biopharma - Shanghai
CMC Technology Transfer Manager- Biologics (New Site)
United Kingdom
Head of USP Manufacturing - Biopharma - Shanghai
South East

To receive a FREE weekly email alert of all the latest pharmaceutical industry jobs added to our database enter your email address below.

Submit | Tell me more...

Sister site:
Our sister site
Job Details
This job has expired. Click here to view similar jobs.

Strategic Analytical Process Expert (New Biological Entities) - UCB

Business Type: Pharmaceutical Company
Job Type: Biology
Job Level: Not Specified
Position: Full Time
Salary: Highly competitive salary plus exceptional additional benefits
Location: Belgium
Reference: PSL 4008
Headquartered in Brussels (Belgium), UCB is a global biopharmaceutical company that combines the infrastructure and expertise of a traditional pharma company with the speed, innovation and entrepreneurship of a biotechnology company. 
UCB is passionate about enabling families with severe diseases to enjoy normal, everyday lives.
  •   A global pharmaceutical company focused in severe diseases with operations in more than 40 countries and global revenues in excess of €3.2 billion in 2010.
  •   Two main research Centers of Excellence - Braine-l’Alleud & Slough
  •   A leader in CNS and Immunology Diseases with approximately 20 large and small molecules in their clinical pipeline spanning 16 diseases, from Crohn’s and Parkinson’s to multiple sclerosis.
  •   A leader in antibody research supported by propriety chemistry and over 30 major R&D partners.

UCB aspire to be the Patient-Centric global pharmaceutical leader transforming the lives of people with severe diseases.

UCB’s vision is to be “the next generation biopharma leader” – through the development of scientific and technological advances to create new opportunities to address the complex interconnections of severe diseases with greater efficiency. 

This can only be achieved by:
  •   Connecting science in new ways
  •   Connecting people
  •   Connecting patients
  •   Passion  Performance
  •   Care
  •   Accountability
  •   Entrepreneurship
  •   Integrity
  •   Innovation
  •   Embracing difference
With the acquisition of Celltech in 2004 and Schwarz Pharma in 2007 and the divestment of the Chemicals division in 2005, UCB has successfully transformed itself from a hybrid pharma and chemical company into a global next generation biopharma leader. UCB is one of the world’s top biopharma players investing more than 25% of its sales in R&D. 
UCB will continue with its model of organic growth, acquisition and partnership to continue to build upon and further develop its product pipeline and R&D success.
Its unique approach in integrating biology and chemistry allows UCB’s discovery, research and development scientists to gain much deeper insights into disease pathways and produce more potent and cost-effective therapeutic solutions.  The fruits of this approach can be seen in UCB’s very rich R&D pipeline with more than 10 molecules in development.
The results are a powerful drug-discovery platform and the ability to target specialists in selected severe-disease areas with a relatively small sales force.
UVB’s focus centres around two key therapeutic areas:
  •   Central Nervous System
  •   Immunology
UCB’s strategy for continued success includes:
  •   Combining the very best biology and chemistry to achieve major breakthroughs
  •   Integrating expertise in large, antibody based molecules with small, chemically derived molecules
  •   Partnering with leaders in the pharmaceutical industry and academia
  •   Leveraging its global scale and intellectual capital
UCB’s ambition is to offer patients innovative new medicines and ground breaking solutions that go beyond the drug.  Through UCB’s commitment to enabling cutting edge scientific research, driven by patients’ needs, people suffering from CNS and immunological disorders are able to lead normal, everyday lives.

Having managed the company through Transformation into a Biopharmaceutical company (2005), Scaling through the acquisition of Schwarz Pharma (2006) and Execution preparing for future growth and implementing the new vision and strategy (2009), UCB is now prepared for Growth.  With new products laying the foundation for future growth, there will additionally be increased investment in the research and development of new products.

Commercial growth and success

UCB is a highly successful biopharmaceutical company, with net sales of €3.1 billion euro in 2009.
Keppra (levetiracetam) reinforced its position as the leading treatment for epilepsy in the US and Europe with a 35% rise in global sales to €1,026 million – Keppra is currently manufactured in Braine l’Alleud.  Keppra remains the market leader in the United States and Europe

Zyrtec (cetirizine) still performed extremely well in the USA with an impressive growth and remains the market leader.

Xyzal (levocetirizine) also increased net sales for the year, further consolidating UCB’s position as a global leader in allergy therapeutics. It is approaching market leadership in Europe and has recently been launched, under a co-marketing agreement in the United States.

The three major recent launches were:
  •   Cimzia (certolizumab pegol), a PEGylated tumour necrosis factor alpha blocker actively used in the treatment of Crohn''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''s Disease and Rheumatoid Arthritis:
  •   Vimpat (lacosamide), approved for use for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 or over
  •   Neupro,  successfully used for the treatment of both Parkinson’s Disease (early stage idiopathic disease signs or symptoms) and Restless Leg Syndrome (moderate to severe disease in adults).
Key Facts and Figures
  •   UCB currently employs over 9,000 people
  •   Company operations exist in more than 40 countries worldwide
  •   2009 net sales were distributed over the USA (35%), Europe (51%), Rest of the World (14%).
  •   2009 net sales were distributed by therapeutic area: Immunology & Allergy (18%), CNS (41%) and Other (41%).
  •   Core products include Cimzia, Vimpat and Neupro
  •   Healthy pipeline with > 14 molecules in clinical development
  •   Global R&D, marketing and sales platform
  •   Over 30 R&D and commercial partners
UCB recently reorganised its R&D organisation in two divisions: UCB New Medicines which covers all aspects from Discovery Research and up to and including clinical Proof of Concept, and Global Product Development, covering late stage, confirmatory trials.

UCB New Medicines is centred around two centres of excellence in Europe: Braine-l’Alleud (Belgium) is focused on the central nervous system, and Slough (UK) covering immunology. 

UCB’s global commercial operations are structured in three business units: Central Nervous System, Inflammation and Primary Care. These are responsible for marketing, medical information and distribution of pharmaceuticals originating from UCB’s research and development in the fields of neurology, allergic/respiratory diseases as well as other primary care diseases. A strong international network of Medical Affairs teams supports these activities.

A significant advance in quality and efficiency to world class standards has also been achieved through several initiatives.  This has included technical innovations within manufacturing processes, thereby reducing costs whilst at the same time ensuring the highest quality and the ability to meet increased demands without any interruption in supply.

UCB’s main manufacturing sites are located in Braine-l’Alleud (Belgium), Bulle (Switzerland), Pianezza (Italy) Rochester (USA), Tokyo (Japan), Vapi (India) and Schwarz Pharma have additional sites in  USA, Ireland, China and Germany.
Further information relating to UCB’s successful product portfolio, pipeline and growth strategy is available from their web site at
Job Description
Primary Purpose of the Role
  •   Establish and steward the essential corporate analytical processes
  •   Participate to create the control strategies to ensure successful new product introductions and lifecycle management.
  •   Provide ownership and oversight for externalized laboratory services 
  •   Provide technical troubleshooting to the QC and externalized labs
  •   Drive best practices through benchmarking and establish network performance indicators
  •   Establish and implement QC data consolidation across sites enabling proactive action plans
  • To define and support implementation of  long term strategy for analytical processes related to NCE/NBE portfolio across UCB sites.
  • To define and support implementation of analytical strategies congruent with UCB RA for optimal new NCE/NBE products introduction through Health Authorities.
Operational Activities
  •   Identify, develop and support implementation of optimal NCE/NBE analytical processes such as specification, stability, methods, transfers, external partnering, data mgt.
  •   Establish and steward the essential corporate analytical processes (specification, stability, methods, transfer, external partnering, data mgt)
  •   Create a simple, global Analytical Quality System congruent with internal UCB customers (DC, BPS Biopharma Process Sciences)
  •   Partner with Technical Leads to create the control strategies to ensure successful new product introductions and lifecycle management by Analytical roadmap: right methods, specs and testing labs, Centralized analytical knowledge mgt for Max Products, Strategic support to Health Authorities,…
  •   Provide ownership and oversight for externalized laboratory services 
  •   Provide technical troubleshooting to the QC and externalized labs
  •   Drive best practices through benchmarking and establish network performance indicators
  •   Develop and steward new processes to allow QC data consolidation across sites enabling proactive action plans (e.g. trend and predictive analyses)
  •   Lead the QC Excellence program to provide a global harmonised and integrated approach to Quality Control Processes across UCB
  •   Keep knowledge up-to-date through litterature reading, attending conferences, visiting other laboratories and benchmarking.
  •   Develop proactively creative and efficient solutions to IP protection.
  •   Planning and resource allocation in a matrix organisation. Evaluate, define and implement optimal external/internal resource balance to provide service to all customers whilst maintaining a lean internal UCB organisation
  •   Provision of high-quality documentation of any technical work performed by the dept. Preparation of summary reports on a monthly, annual basis or ad-hoc.
  •   Working with the Quality Division to ensure compliance with all the appropriate regulations and SOPs and with HSE to ensure application of all necessary security regulations.  Working with Regulatory Affairs to ensure high quality and timely submission documentation.
Person Specification
  •   In depth and broad based analytical laboratory expertise
  •   Experience within Biologics research
  •   Extensive non-clinical drug development experience with Biologics
  •   Broad experience and expertise within all aspects of quality systems
  •   Excellent knowledge of early drug development processes with proven track record of successful contribution to discovery and development projects
  •   Proven track record of successful project leadership
  •   Knowledge of overall drug research, discovery, development processes
  •   Sound understanding of stability and rrlease testing
  •   Ability to communicate effectively with internal and external opinion leaders including pharmaceutical regulatory agencies, e.g. FDA, EMEA
  •   Ability to work in a matrix type environment and successfully drive processes
  •   High performer, strong team-commitment. Innovative with the flexibility and maturity to  manage uncertainty
  •   Ability to work independently and to solve complex problems and contribute to multiple projects
  •   Ability to anticipate program needs and to act accordingly
  •   Interpersonal skills
  •   Team orientated
  •   Self – motivated
  •   Ability to motivate others
  •   Confidence and professional competence to gain credibility and win respect at all levels both within and outside the company
Person Qualities
  •   Dynamic and passionate about science
  •   Open to new technology and new advances
  •   An ability to challenge and change the way in which UCB works
  •   Well organised with an analytical approach to work
  •   A team player
  •   Natural ability to share information and communicate new ideas with others
  •   Able to think globally and strategically
  •   Ability to think independently and make decisions, having the courage to follow instincts and ideas
  •   Open to suggestions from others and harbouring an inclusive style
  •   Ability to adapt easily and take a flexible approach as required
  •   Open and honest with strong, constructive communication and negotiation skills.
  •   Enthusiastic and dynamic, capable of working independently within broad objectives without the need for day-to-day supervision
  •   Comfortable working in a highly visible, high profile role in an organisation with short communication lines and direct access to senior management.
  •   A proactive team player with good communication skills, comfortable interacting with people at different levels, across functions and internationally
  •   Fluent in English and a natural communicator, assertive with well developed presentation, negotiation and persuasion skills. 

UCB are able to offer a highly competitive salary, dependent on experience plus exceptional additional benefits including:
  •   Competitive base salary (13.92 months)
  •   Defined contributory pension plan – company contribution 9.15%
  •   Annual bonus (approximately 15% of gross annual salary, depending on performance, but can be significantly greater for high achievers)
  •   Stock options
  •   Life insurance – 2-4 x annual remuneration (depending on number of dependants)
  •   Hospitalisation / medical insurance
  •   Invalidity insurance
  •   Disability allowance
  •   Representation allowance - €111,55  per month
  •   Meal vouchers
  •   Company car – leasing
  •   Fully expensed car – insurance, servicing and all fuel
  •   Conditional non-resident tax status for candidates coming from outside Belgium, where appropriate and qualified
  •   Fiscal advantages
  •   Relocation / tuition package for children of school age
  •   Use of external tax advisers and consultants
  •   Complete relocation package to include:
  •   Removal of all personal belongings
  •   Reimbursement of the cost of any physical move
  •   Relocation services including paid house hunting trip
  •   Use of external relocation consultants
  •   Settling in allowance
  •   Sponsored language lessons
  • International school fees

Posted: 08/05/2012 | NPJ Ref: 81549
line graphic

Compatible with:

JobMate   Broadbean

Site optimised for Internet Explorer 8+ / Firefox 3+
View a complete Jobs Listing

Credit cards image